Please assess the completion status of the following clinical trial:

Trial Title: Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects ≥18 years of age at Screening.~2. Able and willing to comply with all study procedures.~3. Stable kidney function per Investigator assessment and no known episodes of AKI during the preceding 4 weeks.~4. Scheduled to undergo non-emergent coronary and/or valve surgery(ies) requiring cardiopulmonary bypass, including:~   * CABG alone;~  * Combined CABG surgery/repair of 1 or more cardiac valves;~  * Cardiac valve(s) replacement or repair alone.~5. Females and males of childbearing potential must agree to use 2 forms of contraception, with at least 1 being a barrier method, or abstain from sexual activity for 30 days following study drug administration.~6. Male subjects must agree not to donate or sell sperm for 30 days following study drug administration.~Exclusion Criteria:~1. Presence of AKI (KDIGO criteria) at the time of Screening.~2. Surgery to be performed without cardiopulmonary bypass.~3. Surgery to be performed under conditions of circulatory arrest or hypothermia with rectal temperature \<28°C (82.4°F).~4. eGFR ≤20 mL/min/1.73m2 or need for dialysis.~5. Surgery for aortic dissection or to correct a major congenital heart defect.~6. Administration of iodinated contrast media within 24 hours prior to cardiac surgery or evidence of contrast-induced nephropathy prior to cardiac surgery.~7. Cardiogenic shock or hemodynamic instability within the 24 hours prior to surgery and requirement for inotropes or vasopressors or other mechanical devices, such as intra-aortic balloon counter-pulsation.~8. Requirement for any of the following within 7 days prior to cardiac surgery:~   * Defibrillator or permanent pacemaker;~  * Mechanical ventilation;~  * Intra-aortic balloon counter-pulsation;~  * Left ventricular assist device;~  * Other forms of mechanical circulatory support.~9. Known history of cancer within the past 2 years, except for carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin.~10. Known or suspected sepsis at time of Screening or confirmed or treated endocarditis within 30 days prior to cardiac surgery.~11. Other current active infection requiring systemic antibiotic treatment.~12. Inadequate hepatic function, defined as total bilirubin or alanine aminotransferase or aspartate aminotransferase \>2X the upper limit of normal at time of Screening or Child Pugh Class C liver disease or higher.~13. Any congenital coagulation disorder.~14. Asplenia (anatomic or functional).~15. History of photosensitivity or active skin disease that, in the opinion of the Investigator, could be worsened by RBT-1.~16. Known hypersensitivity or previous anaphylaxis to SnPP or any tin-based product.~17. Serum ferritin \>500 ng/mL or those who have received IV iron within 28 days of Screening.~18. Pregnancy or lactation.~19. Treatment with an investigational drug or participation in an interventional study within 30 days prior to administration of study drug.~20. In the opinion of the Investigator, any disease processes or confounding variables that would inappropriately alter the outcome of the study.~21. Inability to comply with the requirements of the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose RBT-1 (Type: EXPERIMENTAL): Single IV infusion prior to cardiac surgery
- High Dose RBT-1 (Type: EXPERIMENTAL): Single IV infusion prior to cardiac surgery
- Placebo (Type: PLACEBO_COMPARATOR): Single IV infusion prior to cardiac surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).